- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07548242
The Effects of a 12-week In-phase Bilateral Exercise Programme on the Corticospinal Plasticity in People With Progressive Multiple Sclerosis
This study investigates whether a structured exercise program using coordinated movements of both arms can improve brain and motor function in people with Progressive Multiple Sclerosis (MS). Progressive MS is associated with gradual worsening of neurological function, including difficulties with movement, strength, balance, and cognition. Because current medications have limited effects on disease progression, rehabilitation strategies that promote brain plasticity and functional recovery are increasingly important.
In this study, five individuals with Progressive Multiple Sclerosis participated in a 12-week exercise program consisting of in-phase bilateral upper-limb movements performed three times per week. Brain activity related to movement was measured using transcranial magnetic stimulation (TMS), which assessed corticospinal excitability through active motor threshold measurements. Additional clinical tests evaluated walking speed, balance, hand dexterity, muscle strength, cognitive processing speed, fatigue, and quality of life. The study used a single-case experimental design with repeated measurements during baseline and intervention phases to determine whether the exercise program produced measurable neurophysiological and functional changes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Progressive Multiple Sclerosis (MS) is a chronic neurological condition characterized by gradual worsening of neurological function due to damage to the central nervous system. Individuals with progressive forms of MS often experience increasing difficulties with movement, balance, muscle strength, hand function, and cognitive performance. Although disease-modifying medications can reduce inflammatory activity, they have limited effects on the neurodegenerative processes that drive disease progression. For this reason, rehabilitation approaches that promote neuroplasticity-the brain's ability to reorganize and adapt-are considered an important complementary strategy for improving function and quality of life in people with progressive MS.
This study investigates whether a structured exercise program based on coordinated bilateral upper-limb movements can enhance corticospinal plasticity and improve clinical outcomes in people with progressive MS. The corticospinal tract is a major neural pathway responsible for voluntary movement, and damage to this pathway contributes significantly to motor impairment in MS. However, some remaining neural connections may still retain the ability to adapt through activity-dependent plasticity. The study examines whether targeted exercise can stimulate these mechanisms.
Five participants diagnosed with either primary progressive or secondary progressive MS took part in the study. The research used a single-case experimental design with a concurrent multiple baseline approach, in which each participant served as their own control. During an initial baseline period, repeated measurements were collected without intervention to establish stable reference values. The exercise intervention was then introduced at different time points for each participant.
The intervention consisted of a 12-week in-phase bilateral upper-limb exercise program performed three times per week. The training included coordinated movements of both arms performed simultaneously, such as adapted sport-related exercises, functional strengthening activities, and proprioceptive neuromuscular facilitation patterns. Sessions lasted approximately 30-60 minutes and were designed to provide a high number of repetitions while maintaining a safe intensity level.
The primary outcome of the study was corticospinal excitability, measured using transcranial magnetic stimulation (TMS). Specifically, the study evaluated the active motor threshold, a neurophysiological measure reflecting the responsiveness of motor pathways in the brain. Secondary outcomes assessed potential functional changes in walking ability, balance, manual dexterity, upper-limb strength, cognitive processing speed, fatigue, and health-related quality of life.
By combining neurophysiological measurements with clinical assessments, this study aims to determine whether coordinated bilateral exercise can induce measurable changes in brain excitability and functional performance in individuals with progressive MS. The findings may provide preliminary evidence supporting the use of targeted exercise interventions as part of comprehensive neurorehabilitation strategies for people living with progressive MS.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nicosia, Cyprus, 2371
- Cyprus Institute of Neurology and Genetics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of Primary Progressive Multiple Sclerosis (PPMS) or Secondary Progressive Multiple Sclerosis (SPMS)
- Age between 30 and 75 years
- Expanded Disability Status Scale (EDSS) score between 5 and 7
- Ability to understand study procedures and provide informed consent
- Ability to safely participate in an exercise program involving coordinated upper-limb movements
Exclusion Criteria:
- Presence of other neurological diseases affecting the central nervous system (e.g., Parkinson's disease, stroke)
- Metallic implants in the brain contraindicating transcranial magnetic stimulation (TMS)
- History of significant cardiovascular disease (e.g., heart failure, aneurysm)
- History of epilepsy or seizures
- Severe orthopedic disorders (e.g., recent fractures, spine surgery, severe musculoskeletal injury)
- Pregnancy during the study period
- Severe visual impairments (e.g., optic neuritis, diplopia)
- Severe hearing impairments (e.g., deafness)
- Severe spasticity greater than grade 1+ on the Modified Ashworth Scale
- Severe psychiatric disorders (e.g., schizophrenia)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: In-Phase Bilateral Upper Limb Exercise
Participants completed a 12-week exercise program consisting of in-phase bilateral upper-limb movements performed three times per week.
Each session lasted approximately 30-60 minutes and included coordinated exercises involving both arms simultaneously, such as adapted sport-related movements, functional strengthening exercises, and proprioceptive neuromuscular facilitation patterns.
The training was delivered in a circuit format with multiple sets of exercises targeting major upper-limb muscle groups.
Exercise intensity was monitored to remain below 75% of age-predicted maximum heart rate.
The program aimed to provide high repetition movement practice to promote corticospinal plasticity and improve motor and functional outcomes in individuals with progressive multiple sclerosis.
|
The intervention consisted of a 12-week structured exercise program based on in-phase bilateral upper-limb movements, performed three times per week.
During these movements, homologous muscles of both arms were activated simultaneously to promote coordinated bilateral motor activity.
Each session lasted approximately 30-60 minutes and included a circuit of functional exercises, adapted sport-related movements (such as basketball chest and overhead passes), resistance exercises for finger flexion and extension, and proprioceptive neuromuscular facilitation patterns.
The exercises targeted major upper-limb muscle groups and were performed with a high number of repetitions to promote activity-dependent neuroplasticity.
Exercise intensity was monitored using heart rate measurements and maintained below 75% of the participant's age-predicted maximum heart rate to avoid aerobic training intensity.
The program was designed to stimulate corticospinal plasticity and improve motor and functional
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Active Motor Threshold
Time Frame: 12 weeks
|
Active Motor Threshold (aMT) will be assessed using transcranial magnetic stimulation (TMS) over the primary motor cortex during a low-level voluntary contraction of the abductor pollicis brevis (APB) muscle. Surface electromyography (EMG) will be used to record motor evoked potentials (MEPs). The aMT is defined as the minimum stimulation intensity required to elicit motor evoked potentials with an amplitude ≥200 µV in the active muscle. The outcome will be reported as stimulation intensity expressed as a percentage of maximum stimulator output (%MSO). Lower values indicate greater corticospinal excitability. |
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Tests
Time Frame: 12 weeks
|
Secondary outcome measures assessed potential functional and clinical changes associated with the exercise intervention.
Walking ability was evaluated using the Timed 25-Foot Walk Test, in which participants walked a 25-foot distance as quickly and safely as possible and the average time of two trials was recorded, with shorter times indicating better mobility.
Dynamic balance and postural control were measured using the Mini Balance Evaluation Systems Test (Mini-BEST), a 14-item clinical assessment in which higher scores reflect better balance performance.
Manual dexterity was assessed using the Purdue Pegboard Test, which measures fine motor coordination by requiring participants to place small pins into holes on a pegboard using one hand, the other hand, or both hands simultaneously within a limited time.
Upper-limb muscle strength was evaluated using a handheld dynamometer during maximal isometric contractions of major upper-limb muscle groups.
Cognitive processing speed was asses
|
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Autoimmune Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Pathological Conditions, Signs and Symptoms
- Multiple Sclerosis
- Multiple Sclerosis, Chronic Progressive
Other Study ID Numbers
- EEBK/ΕΠ/2022/32
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Progressive Multiple Sclerosis (PMS)
-
Hoffmann-La RocheActive, not recruitingProgressive Multiple Sclerosis (PMS)United States, Spain, Ireland, Canada, France, Bosnia and Herzegovina, Netherlands, Brazil, Denmark, Poland, Czechia, Germany, United Arab Emirates, Hungary, Italy, Mexico, Costa Rica, Morocco, Colombia, Lebanon, Egypt, Panama, Guat... and more
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
Tr1X, Inc.RecruitingMultiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis (SPMS) | Multiple Sclerosis (MS) Primary Progressive | Multiple Sclerosis (MS) Secondary ProgressiveUnited States
-
Rebecca SpainCompletedComparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple SclerosisProgressive Multiple Sclerosis | Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Johns Hopkins UniversityCompletedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on In-Phase Bilateral Upper Limb Exercise Program
-
Cyprus University of TechnologyThe Cyprus Foundation for Muscular Dystrophy ResearchCompletedMultiple SclerosisCyprus
-
Cyprus University of TechnologyCyprus Institute of Neurology and GeneticsCompletedMultiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary ProgressiveCyprus
-
Istituto di Sistemi e Tecnologie Industriali Intelligenti...IRCCS Eugenio Medea; Fondazione Don Carlo Gnocchi Onlus; IRCCS Fondazione Stella... and other collaboratorsRecruitingCongenital and Acquired Neuromotor Disorders | Developmental Coordination Disorder (DCD)Italy
-
Medical University of GdanskGdansk Medical Academy of Applied SciencesActive, not recruitingScapular Dyskinesis | Handball Players | Female AthletePoland
-
Riphah International UniversityRecruiting
-
The Hong Kong Polytechnic UniversityCompleted
-
Beni-Suef UniversityCompletedEffect of Different Types of Aerobic Training on Diastolic Heart Failure PatientsEgypt
-
University of Texas at AustinActive, not recruitingPain Management | Peripheral Neuropathic PainUnited States
-
Princess Nourah Bint Abdulrahman UniversityUnknownHemiplegic Cerebral PalsySaudi Arabia
-
Hamad Medical CorporationNot yet recruiting